Literature DB >> 1833013

Lipoprotein (a) concentrations in postmenopausal women taking norethisterone.

E Farish1, H A Rolton, J F Barnes, D M Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1833013      PMCID： PMC1670922          DOI： 10.1136/bmj.303.6804.694

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Lp(a) lipoprotein: relationship to sinking pre-beta lipoprotein hyperlipoproteinemia, and apolipoprotein B.

Authors:  J J Albers; V G Cabana; G R Warnick; W R Hazzard
Journal:  Metabolism       Date:  1975-09       Impact factor: 8.694

Review 2.  Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis.

Authors:  A D MBewu; P N Durrington
Journal:  Atherosclerosis       Date:  1990-11       Impact factor: 5.162

3.  Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone.

Authors:  E Farish; C D Fletcher; D M Hart; M M Dagen; D E Parkin
Journal:  Clin Chim Acta       Date:  1986-09-15       Impact factor: 3.786

4.  Prevention of bone mineral loss in postmenopausal women by norethisterone.

Authors:  H I Abdalla; D M Hart; R Lindsay; I Leggate; A Hooke
Journal:  Obstet Gynecol       Date:  1985-12       Impact factor: 7.661
  4 in total
  9 in total

Review 1.  Postmenopausal hormone replacement therapy.

Authors:  H S Jacobs; F E Loeffler
Journal:  BMJ       Date:  1992-12-05

2.  Lipoprotein(a)

Authors:  J Scott
Journal:  BMJ       Date:  1991-09-21

Review 3.  Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins.

Authors:  M Seed
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 4.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

5.  Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer.

Authors:  M Morales; N Santana; A Soria; A Mosquera; J Ordovás; J Nóvoa; P Betancor; P F Valerón; B Díaz-Chico; R Chirino
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Interaction of oestrogen and peroxisome proliferator-activated receptors with apolipoprotein(a) gene enhancers.

Authors:  Loretto H Puckey; Brian L Knight
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

Review 7.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 8.  Non-genetic influences on lipoprotein(a) concentrations.

Authors:  Byambaa Enkhmaa; Lars Berglund
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

Review 9.  Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

Authors:  Maria Francesca Greco; Cesare R Sirtori; Alberto Corsini; Marat Ezhov; Tiziana Sampietro; Massimiliano Ruscica
Journal:  J Clin Med       Date:  2020-07-03       Impact factor: 4.964
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.